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Abstract. An epidemic of yellow fever (YF) occurred in the Gambia between May 1978 
and January 1979. Retrospective case-finding methods and active surveillance led to the 
identification of 2 7 1 clinically suspected cases. A confirmatory or presumptive laboratory 
diagnosis was established in 94 cases. The earliest serologically documented case occurred in 
June 1978, at the extreme east of the Gambia. Small numbers of cases occurred in August 
and September. The epidemic peaked in October, and cases continued to occur at a dimin- 
ishing rate through January, when a mass vaccination campaign was completed. The out- 
break was largely confined to the eastern half of the country (MacCarthy Island and Upper 
River Divisions). In nine survey villages in this area (total population 1,531) the attack rate 
was 2.6-4.4%, with a mortality rate of 0.8%, and a case-fatality rate of 19.4%. If these 
villages are representative of the total affected region, there may have been as many as 8,400 
cases and 1,600 deaths during the outbreak. The disease incidence was highest in the O- to 
9-year age group (6.7%) and decreased with advancing age to 1.7% in persons over 40 years. 
Overall, 32.6% of survey village inhabitants had YF complement-fixing (CF) antibodies. The 
prevalence of antibody patterns indicating primary YF infection decreased with age, in con- 
cert with disease incidence. The overall inapparent:apparent infection ratio was 12: 1. In 
persons with serological responses indicating flaviviral superinfection, the inapparent:apparent 
infection ratio was 10 times higher than in persons with primary YF infection. Sylvatic 
vectors of YF virus, principally Aedes furcifer-taylori and Ae. luteocephalus are believed to 
have been responsible for transmission, at least at the beginning of the outbreak. Eighty-four 
percent of wild monkeys shot in January 1979 had YF neutralizing antibodies, and 32% had 
CF antibodies. Domestic Aedes aegypti were absent or present at  very low indices in many 
severely affected villages (see companion paper). In January, however, aegypti-borne YF 2.5 
months into the dry season was documented by isolation of YF virus from a sick man and 
from this vector species in the absence of sylvatic vectors. Thus, in villages where the classical 
urban vector was abundant, interhuman transmission by Ae. aegypti occurred and continued 
into the dry season. A mass vaccination campaign, begun in December, was completed on 
25 January, with over 95% coverage of the Gambian population. A seroconversion rate of 
93% was determined in a group of vaccinees. This outbreak emphasizes the continuing public 
health importance of YF in West Africa and points out the need for inclusion of 17D YF 
vaccination in future programs of multiple immunization. 
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THE GAMBIA 
RTHY ISLAND DIVISION 
UPPER RIVER DIVISION 
LOCALITIES MENTIONED IN TEXT: 
1. Alhamdu ' 9. Sere N'Gai 17. Touba M'Boyenn'e 
2. Juffure 10. Sambuldu 18. SamYoro Gueye 
3. Darusalame 11. Sukuta 19. Médina Yoro Foula 
4. Torro Bah 12. Dingerai 20. Vélingara 
5. Minteh Kundo 13. Sare Bojo 21. MakaGoui 
6. Manduar 14. Sare N'Goba 22. Pakala 
7. Wall i kunda 15. Moddi Jabbu 23. Sali 
8. Forraba 16. Sutuma 
FIGURE 1. Map of the Gambia, showing localities mentioned in text and geographical proximity to the Kédougou 
area of eastern Senegal, where an epizootic of yellow fever has been in progress since December 1976. 
An outbreak of yellow fever (YF) in eastern 
Gambia was suspected on clinical grounds by one 
of us (KC) in October 1978. Preliminary investi- 
gations and serological testing confirmed the etiol- 
ogy by early December, when a country-wide 
mass vaccination campaign was initiated. Be- 
cause of the reported high disease incidence, an 
apparent westward movement of the outbreak 
(toward the capital city of Banjul), and uncertain- 
ty of the vector species involved in YF virus trans- 
mission, a multinational team was organized un- 
der the auspices of the World Health Organization 
(WHO) to conduct an epidemiological study. The 
team began investigations on 2 January 1979; it 
was comprised of physicians and scientists from 
Center for Disease Control, Fort Collins, Colo- 
rado, and Atlanta, Georgia, U.S.A.; L'Office de 
la Recherches Scientifique et Technique Outre- 
Mer (ORSTOM), Dakar, Senegal; the Medical 
Research Council Laboratories, Fajara, the Gam- 
bia; the Medical Research Establishment, Porton 
Down, England; and the Virus Research Labo- 
ratory, Ibadan, Nigeria. 
1 the Ministry of Health (MOH), the Gambia; the 
a. 
Before this outbreak, yellow fever cases had not 
been recognized in the Gambia since 1935.' Se- 
rologic surveys conducted in 1944l and 1955 (I. 
A. McGregor, pers. comm.), however, indicated 
that the virus was either endemic or intermittently 
active in the Gambia. Various serosurveys con- 
ducted in Senegal (which surrounds the Gambia) 
have yielded similar results.' The most recent of 
these surveys confirmed human YF infections in 
two areas of Senegak3, the Kédougou department 
of southeastern Senegal and the upper Casamance 
(the former lies 200 km (125 miles) southeast of, 
and the latter forms the southern border of, the 
Gambia). The Kédougou region is especially im- 
portant in the context of this epidemic. Between 
1976 and 1978, multiple isolations of YF virus 
have been made from Aedes furcifer-taylori, Ae. 
luteocephalus, Ae .  neoafiicanus, and Ae. vittatus 
mosquitoes and from wild monkeys during inten- 
sive field studies conducted by ORSTOM (ref. 5- 
7 and unpublished observations). Human infec- 
t i o n ~ , ~  but no report of disease, have also been 
documented in the Kédougou area. These results 
indicate that an intense sylvatic YF epizootic oc- 
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curred over a 3-year period in gallery forests of 
the Gambian riverine system (Fig. I), and suggest 
a possible source of the present epidemic. 
In this paper we describe the epidemiologic as- 
pects of the human outbreak in the Gambia. A 
companion paper deals with entomologic investi- 
gations. Our results show that this was a large 
epidemic, and they remind us of the importance 
of YF as a continuing public health problem in 
West Africa and emphasize the desirability of in- 
cluding YF vaccine in future multiple immuni- 
zation projects. 
GEOGRAPHICAL CONSIDERATIONS 
The Gambia is the smallest independent state 
in West Africa, with a total area of 4,361 square 
miles, lying between latitude 13’04” to 13’50” 
and longitude 13’47’W to 10’49’W. The country 
is a narrow enclave in Senegal, 7-12 miles wide 
and 295 miles long, bisected lengthwise by the 
River Gambia. There are five political divisions 
(Fig. l), with a total population (1973 census) of 
534,458. The population is predominantly rural 
and dispersed in villages of less than 1,000 inhab- 
itants; the capital (Banjul), lying at the extreme 
western end of the country, has a population of 
41,568, and there are only four other settlements 
with more than 3,000 inhabitants. The typical 
village is composed’of several or more compounds 
in which extended families live in mud-walled, 
thatch-roofed huts within a common wall or 
fence. Immediately surrounding the village and 
extending for some miles around it are cultivated 
fields and partially cultivated savannah accessible 
by footpaths. During planting and harvest times, 
men, women, and children share the labor in the 
fields, and children too young to work are gen- 
erally carried to the farms. 
The population is predominantly Muslim and 
comprised of five major tribal groups, of which 
the Mandingo and culturally related Serahuli are 
the largest, followed by Fulani, Wolof, and Jola. 
Farming (ground nuts, sorghum, rice, etc.) and 
cattle grazing are the major occupational pursuits. 
The country is accessible by road from Senegal, 
from which, however, it is politically and econom- 
ically largely isolated. Movements of people back 
and forth across the b‘orders are, however, com- 
monplace, and during crop harvests as many as 
20,000 laborers from Senegal and Guinée Bissau 
enter the Gambia to work. 
The River Gambia dominates the geography. 
Its source lies 700 miles southeast in the Fouta 
Jallon highlands of Guinea, and before reaching 
the eastern end of the Gambia, it flows through 
the Kédougou area of southeast Senegal, a region 
of epizootic YF in 1976-1978. After reaching the 
eastern border of the Gambia, it flows for 200 
miles through a gently rolling sandstone plateau. 
A mosaic of gallery forest, parkland, open fresh- 
water swamps, and grassy flats characterize the 
area along the river. Further inland, there are typ- 
ical guinea savannah and transitional guinea-su- 
dan savannah habitats, with forests along drain- 
age channels. The last 100 miles downriver is 
characterized by mangrove forest and saline 
swamps bordering alluvial estuarine flats, which 
then give way to savannah uplands. Nonhuman 
primate populations are high throughout the 
country. In the mangrove and riverine forests, 
two species predominate (Colobus badius and 
Cercopithecus aethiops); in the savannah uplands, 
baboons (Papi0 fiapio) and Erythrocebus patus 
are numerous. Galago senegalensis are also pres- 
ent. 
There are distinct rainy (June-October) and dry 
(November-May) seasons. The mean annual rain- 
fall for the past 10 years is 361 in. at Banjul on 
the coast and 296 in. upriver at  Georgetown (Fig. 
1). Rainfall over the past 3 years (1976-1978) was 
not significantly greater than the 10-year average, 
but the rainy season (6.4 months at Georgetown) 
lasted nearly 2 months longer than during the pe- 
riod 1972-1975 (4.0 months). This prolongation 
of the rainy season may have been a factor in the 
YF epizootic extending from areas farther south 
(e.g., Kédougou) to the Gambia. The mean 
monthly temperature is approximately 24°C at 
Banjul and 28°C at  Georgetown. 
MATERIALS AND METHODS 
Search f o r  and surveillance of human cases 
In October 1978 the occurrence of unusual 
numbers of patients with jaundice and a high 
mortality was recognized at Bansang Hospital, 
MacCarthy Island Division (Fig. 1). In Novem- 
ber, AA conducted initial investigations, which 
resulted in the identification of suspect cases who 
had been hospitalized at  Bansang and Basse (Up- 
per River Division), and collection of diagnostic 
serum samples from more than 40 survivors who 
had returned to their home villages. During fol- 
low-up visits in December and January, AA ob- 
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tained second and, often, third serum specimens 
from many of these patients. Serologic tests per- 
formed at  the Medical Research Establishment, 
Porton Down, confirmed the etiology in Decem- 
ber. 
An intensive program of active surveillance was 
initiated in January 1979. Medical personnel at 
hospitals with inpatient services (Bansang, Basse, 
Banjul) and at  selected rural health centers were 
asked to immediately report all cases suspected to 
be YF on the basis of fever and jaundice. Fre- 
quent contact was made with the responsible phy- 
sician or health inspector, and persons with sus- 
pected YF were visited (in the hospital or in their 
home villages) to obtain historical and clinical in- 
formation and diagnostic specimens. Two other 
case-search methods were employed. In one, spe- 
cial teams comprised of health inspectors of the 
Gambian MOH, with or without a member of the 
multi-national team, visited villages in the North 
Bank, MacCarthy Island, and Upper River Di- 
visions; village chiefs and elders were interviewed 
to identify persons who currently had jaundice or 
who had recovered from it, and to obtain serum 
samples. In the other, MOH teams undertaking 
systematic village-to-village YF mass vaccination 
were instructed to inquire about the presence of 
active illness with jaundice and to report suspect 
port patients to the hospital. 
In addition to these means of identifying pa- 
tients, a retrospective search was conducted by 
review of inpatient records at Bansang and Basse 
hospitals and by house-to-house surveys in select- 
ed villages (below). 
1 cases for follow-up or, when appropriate, to trans- 
Village surveys to  de$ne morbidity-mortality rates 
Nine villages in MacCarthy Island and Upper 
River Divisions (Farraba, Sere N’Gai, Sambuldu, 
Sukuta, Dingerai, Sare Bojo, Sare ”Gaba, Mod- 
di Jabbu, and Sutuma; Fig, 1) were surveyed be- 
tween 11 and 25 January. Villages were selected 
on the basis of location within the region most 
severely affected by YF, the occurrence of one or 
more suspect YF cases identified by the active 
case search or review of hospital records, and a 
population size allowing pompletion of the survey 
within 1 day. The complement-fixation (CF) test 
was used exclusively for serodiagnosis because of 
the need to assess recent infection and to distin- 
guish vaccine-induced from wild Y F  viral infec- 
tion. Villages were visited 1 day in advance to 
inform the chief of the purpose of the survey and 
fo solicit the cooperation of village inhabitants. 
During the survey each compound in the village 
was visited; compound members (both those pres- 
ent and absent) were enumerated by age and sex, 
and interviews were held to define a history of 
illness compatible with YI?. Serum samples were 
taken from all those with a history of suspect ill- 
ness and from approximately 25-90% of all other 
village residents. 
For the purpose of retrospective identification 
of suspect YF cases in these surveys, a “case” was 
defined as any illness with the criteria of fever and 
scleral icterus. It was recognized that many other 
etiologies could be responsible for these symptoms 
and that YF often causes illness without jaundice. 
Although more detailed clinical histories were ob- 
tained from many surviving patients, their lack 
of accuracy and completeness (because of trans- 
lation difficulties and the population’s lack of gen- 
eral medical knowledge) dictated a broad and ov- 
ersimplified approach to case identification. 
Other serologic surveys and assessment of 
YF vaccine eficacy 
Serum surveys without a census, or interviews 
for history of illness, were also conducted in four 
villages in the North Bank Division (Torro Bah, 
Aljamdu, Darusalame, Juffure) and one village in 
Lower River Division (Manduar; see Fig. 1). In 
these surveys, villagers were bled on a voluntary 
basis before YF jet-injector vaccination during 
the mass campaign. Inhabitants of two of these 
villages (Torro Bah and Darusalame) were re-bled 
25 days post vaccination to determine the sero- 
conversion rate and vaccine efficacy under routine 
field conditions. This aspect of the investigations 
is described in more detail in another publication.s 
A limited survey was conducted in December 
1978 by staff of the Pasteur Institute, Dakar, OR- 
STOM, and the Ministry of Health, Senegal, in 
areas of Senegal bordering the Gambia (Fig. 1). 
The aim of these surveys was to determine the 
etiology of approximately 30 cases and two deaths 
of acute grippe-like illness accompanied by icterus 
and occasional hemorrhagic manifestations in two 
villages (Touba M’BoyennC and Sam Yoro Gueye; 
Fig. 1). Two hundred and forty-four sera were 
obtained; 55 sera were from the affected villages- 
20 from persons with a history of illness (not well 
defined) and 35 from persons without illness. An 
additional 189 sera were obtained in another vil- 
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TABLE 1 
Number of persons with szrspect yellow fever identged 
by various methods, and number from whom adequate 
diagnostic specimens were obtained, the Gambia, 
1978-1979 
No. 
from 
whom 
adequate 
No. of diag- 
suspect nostic 
cases spec!- 
identi- mens 
Case-finding method fied obtained 
Review of hospital records 118 33 
(January only) 8.5 51  
Active case search by mobile teams 
and hospital surveillance 
Interviews in nine survey villages 68 47 
Total 271 131 
lage in Casamance (Medina Yoro Foula), in Ve- 
lingara 50 km east, and in three villages (Sali, 
Pakala, and Maka Goui ) on the northern border 
of the Gambia. Sera were tested at  the Pasteur 
Institute, Dakar, by CF test against a variety of 
antigens. Forty-three sera were also sent to Dr. 
Karl M. Johnson, CDC, Atlanta, Ga., for indirect 
fluorescent antibody (IFA) tests to detect immu- 
nity to Lassa, Marburg, and Ebola viruses. 
Survey of nonhuman primates 
Monkeys were shot in forested areas near the 
River Gambia in MacCarthy Island Division (near 
Wallikunda; Fig. 1) and in North Bank Division 
(near Aljamdu). Blood was obtained by cardiac 
puncture, and samples of spleen and liver were 
taken for virus isolation attempts. Species, sex, 
and estimated age were recorded. 
Serological and virological techniques 
Blood samples were obtained by antecubital 
venepuncture, with evacuated tubes. For virus 
isolation attempts, whole blood was immediately 
frozen in liquid nitrogen. Sera were separated at 
ambient temperature without centrifugation and 
stored in a mechanical freezer or in liquid nitro- 
gen. Samples were returned to the Fort Collins 
laboratory on Dry 1ce:for testing. Tests for virus 
isolation were performed by intracerebral (IC) 
inoculation of infant Swiss mice (NIH strain). 
Complement-fixation tests were performed in mi- 
crotiter plates by standard  technique^;^ beta pro- 
.$ 
TABLE 2 
Summarized results of diagnostic tests on serafrom per- 
sons with suspected yellow fever (YF),  the Gambia, 
1979 
~ ~~ 
Diagnostic conclusion No. of cases 
Confirmed yellow fever 
Serology only* 10 
Serology and virus isolation 1 
Presumptive yellow fever? 
Inconclusive$ 
Not yellow fevers 
83 
10 
27 
Total 13 1 
* >Fourfold rise in YF CF titer in appropriately timed paired sera: 
antibody pattern (monotypic or mixed homotypic) specific for YF. 
t YF CF titer 3 16 in a single convalescent serum. + YF CF titer = 8 in a single acute or convalescent serum. 
9 YF CF titer < 8 in a single convalescent serum or appropriately timed 
paired sera. 
priolactone-inactivated sucrose acetone-extracted 
antigen of a variety of flaviviruses and Orungo 
virus were used. Plaque-reduction neutralization 
(PRN) tests.against YF, Zika, West Nile, Uganda 
S, Usutu, Koutango, Banzi, and Orungo viruses 
were done in Vero cell cultures, as described else- 
where.*O PRN tests against Ntaya virus were per- 
formed in primary duck embryo cell cultures. Sera 
inhibiting 290% of plaques were considered pos- 
itive. 
Sample ampoules of Y F  17D vaccine that had 
been taken to the field during the mass vaccina- 
tion campaign were returned to the Pasteur Insti- 
tute, Dakar, Senegal, where potency was assessed 
by titration in weanling mice inoculated intrace- 
rebrally and by plaque assay in porcine kidney 
(PS) cells; titers were compared with those ob- 
tained after original manufacture of the same lots 
of vaccine. 
RESULTS 
Search for, and diagnosis of, cases 
Retrospective case-finding methods and active 
surveillance led to the identification of 2 7 1 suspect 
cases of YF; from 131 of the cases, adequate di- 
agnostic specimens were obtained (Table 1). In 11 
of these 131 cases, a diagnosis was confirmed by 
a fourfold or greater rise in CF antibody titer, and 
in one of these cases, YF virus was isolated from 
blood (see below). An additional 83 cases were 
presumptively diagnosed by the presence of CF 
antibodies at  a titer 216 in a single convalescent- 
phase serum (Table 2). In 10 cases no diagnostic 
TABLE 3 
Examples of serological responses, yellow fever cases, the Gambia, 1978-1979 
Complement-fixation titer* 
Case Age/Sex onset obtained YF ZIKA WN DEN-1 UGS Serological response Y F  infection 
Date of Date serum 
1 7lM 29 Oct 
2 2 1/F ?20 Oct 
3 28lM 24 Nov 
4 7/F Oct 
5 241M 9 Nov 
6 1 O/M Sep 
8 2OlF Sep 
7 231F 3 Nov 
9 4OlM 31 Nov 
11 Nov 
7 Dec 
7 Dec 
2 7  Jan 
4 Dec 
2 7  Dec 
24 Jan 
17 Nov 
11 Jan 
16 Jan 
17 Nov 
11 Jan 
2 2  Dec 
<8 
32 
16 
>1,024 
<8 
128 
5 1,024 
128 
256 
31,024 
128 
31,024 
128 
<8 <8 <8 <8 
<8 <8 <8 <8 
<8 <8 <8 <8 
<8 <8 <8 <8 
<8 <8 <8 <8 
<8 <8 <8 <8 
<8 <8 <8 <8 
<8 32 <8 32 <8 16 <8 8 
16 16 64 16 <8 32 
32 16 
64 64 512 3 1,024 
16 32 128 <8 
Monotypic 
Monotypic 
Monotypic 
Monotypic 
Mixed homotypict- 
Mixed homotypic 
Mixed homotypic 
Heterologous cross- 
Heterologous cross- 
monotypic 
reactions 
reactions 
Primary 
Primary 
Primary 
Primary 
Indeterminate 
Indeterminate 
Indeterminate 
Superinfection 
Superinfection 
(Prob. primary) 
* YF, yellow fever; WN, West Nile; DEN-I, dengue 1;  UGS, Uganda S 
t Fourfold higher titer to YF than to other antigens tested. 
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100 
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60 
50 
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20 
10 
0 Clinically suspect not tested 
or serology incbncIusive 
(7 Presumptive or confirmed 
Yellow Fever 
Not Yellow Fever 
+ Fotolcose 
0 Outcome unknown 
FIGURE 2. Epidemic curve, showing the monthly 
distribution of clinically suspect and serologically diag- 
nosed yellow fever (YF) cases and deaths. Cases of jaun- 
dice shown by serologic tests not to be caused by YF are 
also shown. 
conclusion could be reached, and in 2 7  cases YF 
infection was ruled out (at the level of sensitivity 
of the CF test). 
Examples of the serological responses observed 
are given in Table 3. Responses were classified by 
TABLE 4
Frequency of primary and superinfection serologic re- 
sponses by age, yellow fever cases, the Gambia, 1978- 
1979 
Age 
(years) 
0-9 
10-19 
20-29 
30-39 
40 4- 
Unspec. adult 
Age unknown 
No. (%) 
with primary 
yellow fever* 
34 (94) 
12 (86) 
24 (86) 
8 (89) 
2 (67) 
. 2 (67) 
1 (100) 
No. I%) 
with indeter- 
minate or 
superinfection 
patternst 
2 (6)  
2 (14) 
1 ( 1 1 )  
1(33) 
1 (33) 
4 (14) 
O 
Total 
36 
14 
28 
9 
3 
3 
1 
Total 83 (88) 11 (12) 94 
* Monotypic response. 
t Mixed homotypic, nonsepcìfic heterologous, or heterotypic antibody 
responses. 
serological pattern with respect to YF (monotypic, 
mixed homotypic, and heterologous cross-reac- 
tion, either non-specific or heterotypic) according 
to a previously published scheme." This allowed 
an assessment of whether YF infection had oc- 
curred in the absence of previous heterologous fla- 
viviral exposure or represented a flaviviral super- 
infection. As shown in Table 4, 88% of the cases 
had serological responses indicating primary Y F  
infection. The frequency of primary infection was 
slightly (not significantly) higher in the O- to 9-year 
age group and lower in patients over 40 years than 
in YF patients between 10 and 39 years; converse- 
ly, superinfection patterns were more frequent 
with advancing age. 
Chronology and geographic spread of the outbreak 
The epidemic curve is shown in Figure 2. The 
earliest clinically suspect and serologically diag- 
nosed cases occurred in May and June 1978, re- 
spectively. Small numbers of cases were docu- 
mented in August and September. The incidence 
rose dramatically in October, when the epidemic 
peaked. Cases continued to occur at a slightly di- 
minishing rate through January, when the mass 
vaccination campaign was completed and sur- 
veillance activities ceased. As shown in Figure 2 ,  
the case-fatality rate (deaths/clinically suspect and 
laboratory-diagnosed YF cases with known out- 
come X I O O )  was highest in October (47%) and 
higher in September and November (27  and 27%, 
respectively) than in December (8%) and January 
(7%). These findings probably reflect increasing 
recognition of milder, nonfatal clinical forms of 
YF as the outbreak progressed and emphasize 
that the true incidence of YF between September 
and November was undoubtedly much higher 
than our data indicate. 
The incidence of suspect cases shown by labo- 
ratory tests not be be YF was relatively constant 
throughout the epidemic (Fig. 2); there was also 
no difference in age or sex distribution between 
YF and non-YF cases (data not shown). The 
Gambia is hyperendemic for viral hepatitis, a dis- 
ease with which YF was easily confused because 
our surveillance methods allowed detailed and ex- 
pert clinical and historical observations in only a 
few cases. Jaundice from numerous other infec- 
tious and noninfectious causes also occurs in the 
Gambia. 
Figure 3 shows the geographic distribution of 
clinically suspect and diagnosed YF cases. The 
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orCI IRTW ISLAND DIVISION 
mCARTHI S U N D  DIVISION 
I I O~ I WESTERN DIVISION 
M z C l R T H I  ISLAND OIYISION 
I 
WESTERN OIYISION 
I 
WESTERN OIYISION 
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i979 .----.A 
I 
WESTERN DIVISION 
FIGURE 3. Location of serologically diagnosed yellow fever cases (black circles) and clinically suspect (open 
circles) cases, the Gambia, 1978-1979. 
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FEMALES AGEjYrs) MALES 
237 0-9 258 
140 IO 19 161 
1 
I 
150 20-29 129 
I 
I 
107 30-39 61 
56 40-49 85 
I 
71 50t 76 
I 
FIGURE 4. Age and sex distribution of 1,531 resi- 
dents in nine villages in MacCarthy Island and Upper 
River Divisions surveyed in January 1979. 
earliest known case with serological evidence of 
YF infection occurred at the eastern extreme of 
the country in June 1978. All cases occurring be- 
tween May and October were confined to the Up- 
per River and MacCarthy Island Divisions of 
eastern Gambia. In November a single case was 
identified in Mansa Konko, Lower River Divi- 
sion, and in December and January increasing 
numbers of cases were found in the western part 
of the country (Fig. 3). Intensive active surveil- 
lance activities were undertaken in the North 
Bank Division (NBD) of western Gambia in Jan- 
uary 1979 because of the threat that YF might 
reach Banjul (where Aedes aegypti was believed 
to be abundant) and because of the location in the 
NBD of a popular tourist attraction, the village 
of Juffure (the heritage site in Alex Haley's 
Roots '9. Nevertheless, both the distribution of 
cases shown in Figure 3 and the attack rates by 
geopolitical division (Table 5) clearly indicate that 
the epidemic was focused in the eastern half of 
the Gambia, with highest incidence (50-135 cases] 
100,000) in MacCarthy Island Division. 
Census, interview, and serological surveys i n  
nine villages 
The nine survey villages, located in the area 
30-437 inhabitants, with a total population of 
1,531. The age and sex distribution of the survey 
population is shown in Figure 4. A history of ill- 
ness clinically suspected to be yellow fever was 
elicited in 67 cases, 13 (19.4%) fatal. In 39 cases 
a presumptive serological diagnosis was made 
(Table 6). Attack rates were calculated on the ba- 
sis of serologically defined cases (low estimate) and 
of clinically suspect and serologically diagnosed 
cases (high estimate). The low and high estimates 
of clinical YF incidence in the survey villages 
were 2.5 and 4.4%, respectively, with a mortality 
rate of 0.8% (high estimate based on clinically sus- 
pect deaths). The incidence of infection during the 
outbreak, estimated on the basis of YF CF anti- 
body prevalence, ranged from 9.1-66.7% in the 
survey villages (Table 6). There was a rough cor- 
relation between prevalence oÇ CF antibody and 
attack rate in most villages. However, in two vil- 
lages (Dingeri and Sutuma) the antibody survey 
results and morbidity data were discordant. We 
interpret this to reflect either sampling error or 
inaccurate historical information about disease. 
Table 7 shows age- and sex-specific attack rates 
and the prevalence of YF CF antibodies (pre- 
sumed to represent the incidence of recent YF 
viral infection) in the survey villages. The attack 
most severely affected by YF, ranged in size from I 
TABLE 5 
Yellow fever attack aitd mortality rates by geopolitical division, the Gambia, 1978-1979 
Estimated attack 
rate per 100,000 No. cases (deaths) 
Mortality 
With serologic rate per 
Division Population* diagnosis Totalt Low$ High8 100,000B 
MacCarthy Island 110,003 55 (1) 148 (48) 50.0 134.5 43.6 
Upper River 80,944 35 76 (14) 43.2 93.9 17.3 
North Bank 74,058 2 15 (2) 2.7 20.3 2.7 
Lower River 42,914 2 3 (1) 4.7 7.0 2.3 
Western 226,539 O 1 - 0.4 - 
Unknown O 1 
Total 534,458 94 (1) 244 (65) 17.6 45.7 12.2 
- - - 
* 1973 census. 
t Clinically suspect and wrth serologic diagnosis. Does not include Z i  suspect cases shown by serologic testti not to be due to yellow fever (see Table 2). 
$ Based on number of serologically diagnosed cases. 
P Based on total cases [deaths) serologically diagnosed and clinically suspect. 
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TABLE 6
Incidence of yellow fever cases and deaths, case-fatality rates, and prevalence of yellow fever complement$xing 
antibodies in villages of the Gambia, 1978-1979 
Days 
elapsed 
between 
Yellow No. cases (deaths) Estimated 
fever vac- attack rate % 
Survey cination With (%) mortality Case- No. CF5 
village Popu- and serologic (high fatality pos.ltested 
I (Fig. 1) lation survey diagnosis Total* Low? High$ estimate) rate (%) (% pos.) 
Sere "Gaba 
Sukuta 
Sambuldu 
Modi Jabbu 
Farraba 
Sere N'Gai 
Sutuma 
Sare Bojo 
Dingerai 
Torro Bah 
Darusalame 
Alhamdu 
Juffure 
Manduar 
Total 
129 
86 
73 
147 
256 
43 7 
138 
235 
30 
- 
- 
- 
- 
- 
1,531 
5 
1 
2 
4 
4 
6 
8 
3 
O 
O 
O 
1 
1 
O 
9 14 (3) 7.0 10.9 
6 8 (1) 7.0 9.3 
2 4 (O) 2.7 5.5 
1 8 (3) 0.7 5.5 
6 10 (2) 2.3 3.9 
8 15 (4) 1.8 3.4 
3 3 (O) 2.2 2.2 
4 5 (O) 1.7 2.1 
O O O O 
- - - - 
- - - - 
- - - - 
- - - - 
- - - - 
39 67 (13) 2.5 4.4 
2.3 
1.2 
2 .o 
0.8 
0.9 
- 
- 
. -  
- 
- 
- 
- 
- 
- 
0.8 
21.4 
12.5 
37.5 
20.0 
25.7 
- 
- 
- 
- 
- 
- 
- 
- 
- 
19.4 
20147 (42.6) 
14/31 (45.2) 
28/42 (66.7) 
13/47 (27.7) 
11/46 (23.9) 
18/83 (21.7) 
4/44 (9.1) 
28/87 (32.2) 
10121 (47.6) 
12/64 (18.8) 
2/50 (4.0) 
4/29 (13.8) 
3121 (14.3) 
22/86 (25.6) 
1891698 (27.1) 
* Clinically suspect and with serologic diagnosis. 
t Based on number of serologically diagnosed cases. 
f: Based on total cases (deaths) serologically diagnosed and clinically suspect. 
5 Yellow fever complement-fixation titer 316. 
rate was highest in the O- to 9-year age group 
(6.7%) and decreased with advancing age to 1.7% 
in persons over 40 years. The disease incidence in 
persons <20 years of age was significantly greater 
( P  < 0.01) than that in persons >20 years. The 
attack rate was higher (not significantly) in males 
in all but the 340-year age group. The prevalence 
of CF antibodies also was highest in children 0- 
9 years old and declined with age. The antibody 
prevalence in persons <20 years of age was sig- 
nificantly higher ( P  < 0.01) than in older adults. 
I 
CF antibody prevalence was higher in males in 
all but one age group (30-39 years). The differ- 
ences in sex-specific antibody prevalence are sig- 
nificant ( P  < 0.05) in all but the 10- to 19-year 
age group. 
There were 13 deaths with jaundice in the nine 
survey villages between September 1978 and Jan- 
uary 1979; none was decumented by laboratory 
tests. Assuming all 13 deaths were due to YF, the 
mortality rate was 1.0% in males, 0.7% in fe- 
males, and 0.8% overall. The mortality rate was 
TABLE 7
Age and sex-specific yellow fever attack and infection rates, survey villages, the Gambia 
Attack rate* (96) Infection ratet (%) 
(years) Males Females Total Males Females Total 
Age 
0-9 7.0 6.3 6.7 52.8 33.3 43.0 
10-19 5.6 4.3 5.0 39.5 38.7 39.0 
20-29 3.9 2.7. 3.2 44.1 23.8 30.9 
30-39 4.9 1.9 3.0 10.5 39.4 28.9 
340 : 0.6 3.1 1.7 23.1 17.0 20.5 
Total 4.7 4.1 4.4 35.9 29.5 32.6 
* High estimate (serologically diagnosed and clinically suspect casedpopulation X 100). 
t Yellow fever CF (titer 3 1 6 )  prevalence. The number of sera tested in each age-sex grouping ranged from 19 to 63, with a median of 34; 448 sera 
were tested. 
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TABLE 8 
Frequency of primary y e  .w fever (YF)  infectioit and flaviviral sitperinfection in  YF cases altd in persons without 
a history of illness in two villages (Szrkzita and Sambuldu), the Gambia 
No. ill with No. without Inapparent: 
jaundiceltotal illness and apparent 
population seropositivdtested* infection 
Serologic pattern [attack rate (So)] (So POS.) ratio 
Primary Y F  infection? 41188 (2.1) 2/51 (3.9) 2:l 
Flaviviral superinfection$ 41188 (2.1) 24/51 (47.1) 22:l 
Both patterns 8/188 (4.3) 26/51 (51.0) 12:l - Undetermined, inconclusive, or negatives 41188 (2.1) 25/51 (49.0) 
flaviviruses are included in the analysis. 
Ntaya, Koutango, or Banzi viruses. 
* Denominator differs from that in Table 6 because only individuals tested for complement-fixing and neutralization antibodies to YF and seven other 
t YF complement-fixation (CF) titer 2 16; YF neutralization (N) titer 20; no detectable CF or N antibodies to Zika, West Nile, Uganda S, Usutu, 
B Heterologous cross-reactions by CF and N tests between YF and one or more of the flaviviruses tested (see above). 
5 Not tested, anticomplementary reaction, or YF titer s 8. 
highest in children 0-9 years (1.6%) and lower in 
teenagers 10-19 (1.3%) and in young adults 20- 
29 (0.4%). There were no deaths in adults over 30 
years. The case fatality rates in persons 0-9 and 
10-19 years of age were similar (24 and 27%) and 
were higher than in persons 20-29 (11%; not sta- 
tistically significantly different) and also higher 
than in persons >30 years (O%, again not statis- 
tically significantly different). 
In order to define the ratio of inapparent to ap- 
parent YF infections, we examined CF and 
plaque reduction neutralization test results in per- 
sons with and without a history of illness in two 
survey villages, Sukuta and Sambuldu. These vil- 
lages were selected for analysis because the attack 
rates were high and because YF vaccinations had 
been performed only 1 and 2 days prior to bleed- 
ing (as compared to 3-8 days in other survey vil- 
lages with YF cases). In the two villages there 
were eight cases of YF which could be serologi- 
cally defined, four with primary YF infections 
(monotypic CF and neutralizing [NI antibody pat- 
terns) and four with superinfection (mixed homo- 
typic or heterologous cross-reaction) patterns. The 
incidence of primary and superinfection without 
illness was 3.9 and 47.1%, respectively (Table 8). 
The ratio of inapparent:apparent infections was 
estimated to be 12:1 overall, 2:1 in persons expe- 
riencing primary YF infection, and 2 2 1  in per- 
sons with serologic patterns indicating previous 
exposures to one or more heterologous flavivirus- 
es. The flaviviruses responsible for previous in- 
fection were partially elucidated (see Neutral iz ing 
an t ibody  prevalence below). 
In addition to the nine survey villages in the 
severely affected zone, serological surveys were 
conducted at  five locations in western Gambia 
(Fig. 1 and Table 6). The CF antibody prevalence 
ranged from 4.0 to 18.8% in four villages in North 
Bank Division and was 25.6% (comparable to 
several sites in the epidemic region) at  Manduar 
in Lower River Division. 
TABLE 9
Yellow fever complentent-jìxation (CF) and plaque-re- 
duction neutralization test (PRNT) results, selected 
villages, the Gambia, 1979 
No. positivdtested Vaccination 
(% POS.)* [no. days 
Village before 
(see Fig. 1) CF PRNT sample) 
Sambuldu 28/42 (66.7) 28/29 (96.6) Yes (2 days) 
Dingerai 10121 (47.6) 20/22 (90.9) No 
Sukuta 14/31 (45.2) 33/33 (100) Yes (1 day) 
Manduar 22/86 (25.6) 69/71 (97.2) No 
Torro Bah 12/64 (18.8) 14/38 (36.8) No 
Darusalame 2/50 (4.0) 6/26 (23.1) No 
* Sera tested against YF (Asibi) virus at final dilutions of 1:2. 1:20, 
1:ZM). Of the 170 sera with detectable YF neutralizing antibodies, 121 
(71%) had antibody titers P200 and 143 (84%) had titers 320. 
Neutral iz ing ail t ibody prevalence 
Plaque-reduction neutralizing-antibody preva- 
lences in six villages in which vaccinations either 
had not been performed or had been done 1-2 
days before bleeding are shown in Table 9. In two 
villages (Darusalame and Torro Bah) in the North 
Bank Division, the neutralizing-antibody preva- 
lence was 23 and 37%, respectively, correspond- 
ing to relatively low rates of CF antibody. In 
Manduar (Lower River Division) and in three vil- 
lages in eastern Gambia, however, 91-100% of 
the population was immune. This indicated ex- 
tremely high rates of YF virus infections, which, 
I 
1- 
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TABLE 10 ' /  
Prevaleme of neutralizing a d b o d i e s  to jlavivimises in residents of two villages (Sukuta and Sambuldu) without a I 
history of clinical yellow fever (YF vaccinations were pevformed 24-28 hours prior to bleeding) 
Percent positive* 
No. 
Age tested YF ZIKA W N  NTA usu UGS* KOU BAN 
0-9 5 100 40 O O O O O O 
10-19 9 1 O0 89 O O 33 33 O 33 
I 20-29 18 100 94 22 28 39 17 11 17 
530  30 97 90 33 17 33 27 27 33 
Total 62 98 90 23 16 34 23 16 26 
* YF = yellow fever; WN = West Nile; NTA = Ntaya; USU = Usutu; UGS = Uganda S; KOU = Koutango; BAN = Banzi. 
if not acquired during the 1978-1979 outbreak, 
was at  least relatively recent (since over 90% of 
children under 10 years of age bled in Sam- 
buldu, Sukuta, and Dingerai had neutralizing an- 
tibodies). 
In the villages (Sambuldu and Sukuta) used to 
define the YF inapparent:apparent infection ratio, 
the prevalence of N antibodies to heterologous fla- 
viviruses was determined (Table 10). Zika virus 
appeared to be most frequently responsible for 
prior infections; over 90% of individuals over 10 
years old had Zika antibodies. Thirty-eight of 56 
(68%) Zika antibody-positive individuals had ti- 
ters 2160. ,Antibody titers S160 were found only 
in 2 of 10 individuals positive to Ntaya virus, and 
in 1 of 2 1  individuals positive to Usutu virus. 
Non-human primate serosumey 
No virus was recovered from blood, spleens, or 
livers of 19 monkeys. Sixteen monkeys (84%) had 
YF HI and N antibodies and 6 (32%) had CF 
titers 2 16 (Table 11). Serological reactions were 
specific for YF in at  least 14 of the 16 seropositive 
animals; one monkey had evidence of Zika viral 
infection. Juveniles and adults had similar anti- 
body prevalence rates. Seropositive animaIs were 
collected both in eastern (13/16 N-positive) and 
western Gambia (3/3 N-positive). 
Isolation of yellow fever virus >om a patient 
ifa North Bank Division, January 1979; 
evidence f o r  Aedes aegypti- 
transmitted infection 
During active surveillance activities, attention 
was drawn to the village of Minteh Kunda, pop- 
ulation 890 (Fig. I), where a 40-year-old man had 
died on the 7th day of illness (IO January) with a 
syndrome compatible with YF. On 1.2 January a 
house-to-house search for cases in the village re- 
vealed two acutely sick persons with onsets of fe- 
TABLE 11 
Prevalence of yellow fever (YF) antibodies in wild monkeys, the Gambia, 1979 
Number (%) YF positive* 
Number 
Species Age tested 
Colobus badius Ad 11 
JUV 1 
Cercopithecus Ad 3 
aetltiops JUV 4 
Total Ad 14 
Jiuv 5 
Total 19 
Indeterminate 
YF  monotypic or heterotypic 
* HI  20, C F  16. 
t Homotypic HI  antibody to Zika virus, negative to YF  by N test. 
J 
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ver 2-3 days before. Blood samples were ob- 
tained, and yellow fever virus (strain 79H-327) 
was isolated from a sample from one of the pa- 
tients and identified by CF and N tests. The pa- 
tient was a 20-year-old man with fever, relative 
bradycardia, headache, severe weakness, lumbos- 
acral pain, conjunctival injection, and red tongue 
at  the’ tip and edges. Jaundice developed subse- 
quently. The patient was re-bled during conva- 
lescence (on 28 January), and a CF test serologic 
conversion to YF virus from a titer of <8 to 32 
was demonstrated. 
An Aedes aegypti larval survey in the village 
revealed a high Breteau index (104 positive con- 
tainersllO0 houses). l3 Biting collections using bait- 
men were conducted between 1500 and 2000 
hours with a total of 80 manhours expended. Six- 
ty-four female Ae. aegypti were collected and 
tested for virus at the Pasteur Institute, Dakar. 
Two strains of YF virus were recovered.13 No 
sylvatic Y F  vectors were captured in this village 
or at any other location in the Gambia in January, 
despite considerable effort. l3 
Mass vaccination campaign and 
vaccination efficacy 
In December 1978, a country-wide vaccination 
campaign was begun. The vaccine used was 17D 
YF vaccine manufactured at  the Pasteur Institute, 
Dakar, Senegal; it was generally administered by 
jet-injector, but sometimes, when the equipment 
failed, by syringe and needle. By 31 January over 
546,000 vaccinations had been done, representing 
coverage of approximately 95.5% of the estimated 
1978 population. From the antibody surveys con- 
ducted in several villages in eastern Gambia, nat- 
urally-acquired immunity rates were so high by 
late January that further interhuman YF virus 
transmission was precluded and vaccinations 
were unnecessary (Table 8). 
Because most areas of the Gambia are remote 
from towns with electricity and mechanical re- 
frigeration equipment, 17D YF vaccine was 
brought to the field in freeze-packs (“cold dogs”), 
and the cold chain was often tenuous and threat- 
ened by interruption. It was therefore important 
to assess the efficacy of the vaccination campaign 
and to investigate the potency of vaccine that had 
been taken to remote areas. 
Neutralization tests were performed on sera 
from 58 individuals at Torro Bah and Darusalame 
villages (see Fig. 1) bled before and 25 days after 
jet-injector vaccination. Seventeen individuals 
(29%) had YF N antibodies in their sera before 
vaccination. (Five of these showed a rise in N 
antibody titer after vaccination.) Of the remaining 
41 persons without prevaccination antibodies, 38 
(93%) seroconverted. The seroconversion rate was 
similar in those (13 persons) withour prior heter- 
ologous flaviviral experience (92%) and in those 
(28 persons) with prevaccination heterologous HI 
flaviviral antibodies (93%). Seroconversion was 
defined as a rise in PRNT titer from undetectable 
in undiluted serum to 5 2  (i.e., 90% plaque re- 
duction by undiluted serum mixed with 100 
plaqÚe-forming units of 17D YF virus). The dis- 
tribution of titers in postvaccination sera from 41 
nonimmune vaccinees was: titer = 2 ,  14 persons; 
titer = 20, 17 persons; titer 2200, 7 persons. 
At least two ampoules of each of four lots of 
17D vaccine were titrated after having been 
brought to the field during the vaccination cam- 
paign, and the titers were compared to initial ti- 
ters obtained after manufacture of each lot. The 
potency was reduced in some ampoules but equal 
or higher than original titers in others. In every 
case, the potency of vaccine brought to the field 
was adequate and met WHO specifications. 
! 
Investigations conducted in 
neighboring Senegal 
In the villages of Touba M’Boyenné and Sam 
Yoro Gueye, the prevalence of YF CF antibodies 
in persons with a history of illness (25%) was iden- 
tical to that in controls without illness. Overall, 
14% of sera collected in Casamance, 4% at Vélin- 
gara, and 2% in villages on the northern border 
or the Gambia were Yf seropositive. A high prev- 
alence of Orungo CF ’anitbodies was found, but 
there was no association with history of illness. 
Surprisingly, 8 of 29 sera from a single village 
(Touba M’BoyennC) contained IFA antibodies to 
Ebola virus at titers 2 4  (3 sera positive at  titers 
216). There was no clear evidence for an associ- 
ation between Ebola virus infection and history 
of illness. I 
Orungo virus infections 
During an outbreak of yellow fever in Nigeria 
in 1973-1974, a high frequency of concomitant 
infections with an unrelated virus (Orungo) was 
documented. l4 This orbivirus had previously been 
associated with epidemic febrile illness and pos- 
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TABLE 12 
Prevalence of complement-fixing (CF) and neutralizing 
(N) antibodies to Orungo vinis (UGMP-359), by vil- 
lage, the Gambia, 1979 
~~ ~ 
Orungo virus 
No. CF No. N 
pos./tested poshs ted  
Village (% pos.) (% POS.) 
Dingerai 
Sare Bojo 
Manduar 
Sere "Gaba 
Sambuldu 
Farraba 
Modi Jabbu 
Sere N'Gai 
Sukuta 
JuffurelAlhamdu 
Sutuma 
Torro Bah/ 
Total 
Darusalame 
13/21 (61.9) 
35/61 (57.4) 
34/62 (54.8) 
24/46 (52.2) 
20142 (47.6) 
20147 (42.6) 
18/47 (38.3) 
25/82 (30.5) 
8/30 (26.7) 
4/17 (23.5) 
9/45 (20.0) 
5/38 (13.2) 
215/538 (40.0) 
18/23 (78.3) -* 
55/70 (78.6) 
30/42 (71.4) 
- 
- 
- 
- 
22/36 (61.1) - 
- 
- 
1251171 (73.1) 
* Not tested. 
sible deaths,I5 and although jaundice was not a 
described feature of the illness caused by this virus 
it was of interest to include Orungo in the sero- 
epidemiological analysis of the Gambian out- 
break. 
A high prevalence of Orungo CF and N anti- 
bodies was found in the village populations sam- 
pled (Table 12) ,  and many sera contained CF an- 
tibodies to both YF and Orungo viruses. The 
prevalence of Orungo CF antibodies was not sig- 
nificantly ( P  > 0.2) higher in sera from patients 
with jaundice who were suspected of having, but 
were not shown to have, YF (61%) than in sera 
from persons with serologically confirmed or pre- 
sumptive cases (47.3%), as shown in Table 13. 
Three serological conversions to Orungo were 
documented in patients qyith jaundice (Table 14). 
In two cases, seroconversion to Y F  also was 
shown. The chronology of illness and change in 
Orungo antibody titer suggested that the virus 
was not implicated in any of the patients' illnesses. 
DISCUSSION 
Yellow fever is a recurrent epidemic disease in 
West Africa. 'During the last decade, important 
outbreaks have been recorded in 1969 (involving 
more than 15,000 cases in Nigeria, Upper Volta, 
Ghana, Mali, and TogoI6), and in 19701' and 
197414,18 in Nigeria (involving an estimated 786 
TABLE 13 
Prevalence of Oningo viral CF antibodies among cases 
clinically szispected to be yellow fever (YF), by Y F  
serodiagnostic category, the Gambia, 1978-1979 
Yellow fever serologic No. No. Orungo 
interpretation cases podtested % 
Presumptivelconfirmed 94 44/93 47.3 
Inconclusive 10 5/10 50.0 
Negative 27 16/26 61.5 
and 45 cases, respectively). The present epidemic 
in the Gambia is an important one in terms of 
morbidity and mortality. Although only 244 clin- 
ical cases (65 fatal) were recognized by various 
case-finding methods (Table 5), detailed village 
surveys (Table 6) indicated high attack rates (2.5- 
4.4%), with a mortality rate, based on clinically 
suspect cases, of 0.8%. Assuming for purposes of 
discussion that the incidence in the survey villages 
is representative of eastern Gambia as a whole 
(MacCarthy Island and Upper River Divisions, 
population 190,947), there may have been as 
many as 8,400 YF cases and 1,600 deaths during 
the epidemic. 
The incidence of clinical YF and YF virus in- 
fection (determined by CF antibody prevalence) 
was highest in children 0-9 years of age and was 
significantly higher in persons <20 than in those 
>20 years of age (Table 7). This is best explained 
by the high frequency of primary YF infection in 
young persons. Eighty-eight percent of all sero- 
logically diagnosed clinical YF cases were in in- 
dividuals with primary infections (Table 4). As 
the frequency of serological responses indicating 
flaviviral superinfection increased with age, the 
incidence of disease decreased. 
A possible source of misinterpretation of the CF 
antibody prevalence data was the administration 
of 17D YF vaccine up to 8 days before sera were 
obtained in the survey villages (Table 6). Yellow 
fever vaccine has been shown to induce serocon- 
version or significant CF antibody titer rises in up 
to 46% of persons with prevaccination YF or het- 
erologous flavivirus experiences,8 but not in im- 
munological virgins. Thus, 17D YF vaccination 
may have been responsible for some of the CF 
seropositives detected among persons with flavi- 
viral superinfection patterns (Table 4). Conse- 
quently, we were able to analyze the effect of 
heterologous immunity on attack rate and 
inapparent:apparent infection ratio only in a small 
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TABLE 14 
Cases of suspected yellow fever in which serologic conversions to  Orultgo virus were demonstrated, probably vnre- 
lated to  the cuwent illness 
Complement-fixation titer* 
Illness 
Case Age Sex' onset Serum YF ZIK WN D-1 UGS ORU 
1 24 M Oct 22 Nov <8 <8 
7 Dec <8 <8 
27 Jan <8 <8 
2 7 M 29 Oct 17 Nov (8 <8 
7 Dec 32 <8 
27 Jan 16 <8 
3 Ad M Nov 17 Nov 64 <8 
7 Dec 64 <8 
27 Jan 128 <8 
<8 
256 
32 
<8 
8 
128 
<8 
<8 
256 
* YF, yellow fever; ZIK, Zika; WN, West Nile; D-1, dengue type 1; UCS, Uganda S; ORU, Orungo 
sample of villagers who received 17D YF vaccine 
1-2 days before the serologic survey. In this 
group, primary YF infections were infrequent. 
The ratio of inapparent to apparent infection was 
approximately 10 times greater in persons with 
prior flaviviral experience than in immunological 
virgins. The flaviviruses responsible for the back-! 
ground of immunity in this population were par- 
tially elucidated by N tests (Table 10). Homolo- 
gous (YF) immunity was present in nearly 100% 
of the inhabitants of villages in eastern Gambia, 
and this finding was not explained by administra- 
tion of YF vaccine (Tables 9, 10). Homologous 
(YF) immunity was therefore probably responsi- 
ble for the reduction in disease incidence in many 
older individuals and in those with superinfection 
serological responses, although heterologous fla- 
viviral immunity (particularly to Zika virus; Ta- 
ble 10) may have also played a role. Because we 
were unable to study either the immunological 
background of fatal cases or the relative clinical 
severity of illness, we could not determine to what 
extent background immunity influenced outcome 
of infection. The higher case-fatality rate in young 
persons suggested, however, that the disease was 
more severe in persons without prior flaviviral 
experience. 
The incidence of disease and infection was 
higher in males than in females. This sex differ- 
ence has been noted in other outbreaks of sylvatic 
YF in West Africa.lS Although we have no sup- 
porting data, we hav& observed that males tend 
to remain out-of-doors and outside village con- 
fines for longer periods after sundown than fe- 
males. This behavioral difference may explain the 
increased exposure of males to sylvatic vectors of 
YF virus. 
The geographic and chronologic distribution of 
YF cases, the high prevalence of immunity in 
nonhuman primates, and information from our 
entomologic inve~tigationsl~ all indicate that this 
was, a t  least a t  the beginning, an epidemic of syl- 
vatic YF. As the outbreak progressed, interhu- 
man transmission was also assured by domestic 
Ae.  aegypti, at  least in those localities where this 
vector was prevalent. The outbreak peaked dur- 
ing the last months of the rainy season, at a time 
when one would expect peak populations of syl- 
vatic vectors to be p re~en t .~*~O Limited human 
bait collections made in November 1978 at local- 
ities in MacCarthy Island Division by workers of 
the Medical Research Council, Fajara document- 
ed the presence of two potential sylvatic vectors 
(Aedes furcifer-taylori group).?' In addition, Ae. 
luteocephalus larvae were recovered from tree 
holes at Wallikunda, which had been artificially 
flooded in January. l3 Extensive surveys in Janu- 
ary showed domestic Ae. aegypti (breeding in 
water storage jars) to be absent in 11 villages or 
present a t  a very low rate (Breteau indices < 5) 
in two of 2 1  villages in MacCarthy Island and 
Upper River Divisions. However, the peridomes- 
tic potential breeding sites for Ae. aegypti were 
generally numerous (although in January dry), 
and the prevalence of this species could have been 
much greater during the rainy season. Entomo- 
logic investigations were conducted in six of the 
nine census-serosurvey villages;13 Ae. aegypti Bre- 
teau indices were O in three villages (Sambuldu, 
Sikuta, Sare "Gaba), and indices of 1.5, 9.6, and 
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14.0 were found in Sere N'Gai, Sare Bojo, and 
Modi Jabbu, respectively. In two of 2 1  localities 
surveyed in eastern Gambia, a high risk of 
aegypti-borne YF was determined on the basis of 
Breteau indices >50. Similarly, in the North 
Bank Division, Ae.  aegypti breeding was docu- 
mented in January in three of six localities, in- 
cluding one (Minteh Kunda) with a very high Bre- 
teau index (104.0), where YF virus was isolated 
from a sick patient and from two pools of A e .  
aegypti mosquitoes collected on 12 January, at a 
time when sylvatic vectors were absent. l3 This 
observation, and the laboratory documentation of 
15 YF cases in the Gambia with disease onset in 
January, suggest that, with the rapid decline of 
sylvatic vector populations in the early dry season, 
YF virus transmission continued by the agency of 
A e .  aegypti vectors in localities supporting do- 
mestic breeding. 
The occurrence of the first recognized cases at  
the extreme eastern end of the Gambia in May 
and June suggests that the virus may have been 
introduced as part of an epizootic wave in monkey 
populations inhabiting gallery forests along the 
Upper River Gambia. The known occurrence of 
an epizootic at Kédougou, 125 miles upriver from 
the Gambia, since at  least December 1976,"7 
supports this suggestion. As pointed out in a com- 
panion paper,13 unusual prolongation of the rainy 
season during this interval may have allowed vi- 
rus activity to expand northwest from the Kédou- 
The recent findings that YF virus is transovar- 
ially transmitted in Ae.  furcifer-taylori in na- 
tureS7 suggest that the virus may persist in ar- 
thropod reservoirs in the Gambia. The high 
prevalence of natural or vaccine-induced immu- 
nity in the human and monkey populations, how- 
ever, make it unlikely that a high rate of virus 
transmission will occur in 1979-1980. 
The successful efforts to rapidly vaccinate the 
population of the Gambia are noteworthy, and 
reflect the experience and expertise gained during 
the smallpox eradication campaign of the 1960s. 
In a small group of individuals, a vaccine-induced 
seroconversion rate of 93% was demonstrated; 
this rate is somewhat lower than rates described 
in other s t u d i e ~ . ' ~ ~ ~ ~  The methods used to assess 
immunity in these studies have differed; we used 
the PRNT; others have used the mouse protection 
or HI test. Many other factors, such as the age 
distribution and nutritional statusz4 of the popu- 
lation, as well as variations in sampling, could 
gou focus. 
account for observed differences in seroconversion 
rates. Our study differed from other studies in that 
we were assessing vaccine efficacy under true field 
conditions rather than as part of a planned study. 
The present outbreak reminds us that YF con- 
tinues to be a major threat in Africa. The high 
attack rate, and the case-fatality rate of nearly 
20% in this epidemic, illustrate the public health 
importance of Y F  and contrast with the relatively 
rare occurrence of other viral hemorrhagic infec- 
tions, such as Lassa fever, which have been highly 
publicized in recent years. The abundance of the 
classical urban vector of YF, Ae.  aegypti, in cities 
and larger towns in West Africa raises the spectre 
of large urban epidemics of the disease, the risk 
of which is attested to by the intermittent occur- 
rence of urban, aegypti-borne outbreaks of chi- 
kungunya. These observations are especially dis- 
turbing because a safe, easily administered YF 
vaccine has been available for decades and can be 
administered effectively (as shown by our study 
and many others) under field conditions. Despite 
its availability and relatively low cost, 17D vac- 
cination has been used in many African countries 
only in response to disease outbreaks. As multiple 
immunization programs are considered for use in 
Africa, it would be appropriate to include 17D as 
an integral component. 
ACKNOWLEDGMENTS 
The authors gratefully thank the many individ- 
uals of the Gambian MOH who assisted in these 
epidemiological studies and the mass vaccination 
campaign. We are grateful for the cooperation of 
physicians at  Bansang Hospital who comprised a 
team from the People's Republic of China. Es- 
pecial thanks are due the Medical Research Coun- 
cil, Fajara; the Director, Dr. I. A. McGregor, and 
his staff greatly assisted in solving logistical prob- 
lems and provided laboratory space and housing. 
Similarly, thanks are due to USAID for providing 
administrative assistance and vehicles. Dr. C. H. 
Calisher and Mr. D. J. Muth assisted greatly in 
the serological studies. 
REFERENCES 
1. Bonnel, P. J., and Deutschman, Z., 1954. La fièvre 
jaune en Afrique au cours des années récentes. 
2. Bres, P., 1970. Données récentes apportées par les 
enquêtes sérologiques sur la prévalence des ar- 
Bull. W.H.O., I l :  325-389. 
I I 
MONATH ET AL. 
bovirus en Afrique avec référence speciale a la 1980. Yellow fever in the Gambia, 1978-1979: 
fièvre jaune. Bull. W.H.O., 43: 223-267. Entomological aspects and epidemiological cor- 
3. LeGonidec, F., and Dhiver, F., 1973. Le virus de relations. Am. J. Trop. Med. Hyg., 29: 929-940. 
la fièvre jayne et autres arbovirus dans le Sénégal 14. Tomori, O., El-Bayoumi, M. S. M., and Fabiyi, 
Oriental. Etude des sérums humains. Bull. Soc. A., 1976. Virological and serological studies of 
Pathol. Exot., 66: 603-615. a suspected yellow fever virus outbreak in Ma- 
4. Renaudet, J., Jan, Ch., Ridet, J., Adam, C., and budi area of Benue Plateau State of Nigeria. Ni- 
Robin, Y., 1978. Enquête sérologique pour les ger. Med. J . ,  6: 135-143. 
arbovirus dans la population humaine du Séné- 15. Fabiyi, A., Tomori, O., and El-Bayoumi, M. S. 
gal. Bull. Soc. Patltol. Exot., 71: 131-140. M., 1975. Epidemics of a febrile illness associ- 
5. Anonymous, 1978. Yellow fever in 1977. W.H.O. ated with UgMP 359 virus in Nigeria. W .  Afr. 
Wkly. Epidemiol. Rec., 48: 345-349. Med. J., 23: 9-11. 
6. Cornet, M., Robin, Y . ,  Heme, G., Adam, C., Re- 16. Chambon, L., Digoutee, J.-P., Cornet, M., and Ro- 
naudet, J., Valade, M., and Eyraud, M., 1979. bin, Y., 1972. Données récentes sur la situation 
Une poussée épizootique de fièvre jaune selva- épidémiologique de la fièvre jaune en Afrique 
tique au Sénégal oriental. Isolement du virus de Noire. Bull. Soc. Pathol. Exot.,  65: 673-683. 
lots de moustiques adultes mâles et femelles. 17. Monath, T. P., Wilson, D. C,, Lee, V. H., Stroh, 
Med.  Malad. Infect., 9: 63-66. G., Kuteyi, K., and Smith, E. A., 1973. The 
7. Germain, M., Cornet, M., Mouchet, J., Herve, J. 1970 yellow fever epidemic in Okwoga District, 
P., Salaun, J. J., Camicas, J. L., Hervy, J. P., Benue Plateau State, Nigeria. 1. Epidemiological 
Chippaux, A., Saluzzo, J. R., Cordellier, R., Su- observations. Bull. W.H.O., 49: 113-12 1. 
reau, P., Eyraud, M., Huard, M., Renaudet, J., 18. Anonymous, 1975. Yellow fever in 1974. W.H.O. 
Adam, C., Ferrara, L., Heme, F., Digoutte, J. Wkly. Epidemiol. Rec., 50: 297-301. 
P., and Robin Y. Recent progress in epidemio- 19. Carey, D. E., Kemp, G. E., Troup, J. M., White, 
logical studies on sylvatic yellow fever in Afri- H. A., Smith, E. A., Addy, R. F., Rom, A. L. 
ca. Int. Symp. “New Aspects in Ecology of Ar- M. O., Jones, E. M., Bres, P., and Shope, R. 
boviruses,” Slovak Academy of Sciences, E., 1972. Epidemiological aspects of the 1969 
Smolenice, June 11-15, 1979. In press. yellow fever epidemic in Nigeria. Bull. W.H.O., 
C. J., Calisher, C. H., and Fitzgerald, S. A., 20. Germain, M., Herve, J. P., and Geoffroy, B., 
1980. Limitations of the complement-fixation test 1977. Variation du taux de survie des femelles 
for distinguishing naturally acquired from vac- d’Aedes afiicanus (Theobold) dans une galerie fo- 
cine-induced yellow fever infection in flavivirus restiere du sud de l’Empire Centrafricain. Cah. 
hyperendemic areas. Am. J. Trop. Med. Hyg., O.R.S.T.O.M. Ser. Entomol. Med. Parasit., 15: 
9. Casey, H. L., 1965. Standardized diagnostic com- 2 1 .  Port, F. R. and Wilkes, T. J., 1979. Aedes (Dicer- 
plement-fixation method and adaptation to micro omyia) furcifer-taylori and a yellow fever out- 
test. Public Health Monograph N o .  74, US. De- break in the Gambia. Trans. R. Soc. Trop. Med. 
10. Monath, T. P., 1976. Togaviruses, bunyaviruses, 22. Meyer, H. M., Jr., Hostetler, D. D., Jr., Bernheim, 
and Colorado tick rever virus. Pages 456-462 i n  B. C., Rogers, N. A., Lambin, P., Chassary, A., 
N. R. Rose and H. Friedman, eds., Manual of Labusquière, R., and Smadel, J. E., 1964. Re- 
Clinical Immunology. American Society for Mi- sponse of Volta children to jet inoculation of com- 
crobiology, Washington, D.C. bined live measles, smallpox, and yellow fever 
11. Monath, T. P., Wilson, D. C., and Casals, J., vaccines. Bull. W.H.O., 30: 783-794. 
1973. The 1970yellowfever epidemic in Okwoga 23. Gateff, C., Robin, Y . ,  Labusquière, R., Le- 
District, Benne Plateau State, Nigeria. 3. Sero- Gonidec, G., LeMarinier, G., and Bradley, M., 
logical responses in persons with and without pre- 1972. Comparaison de deux vaccins antimarils 
existing heterologous group B immunity. Bull. administrés par injecteur sous pression sans aig- 
W.H.O., 49: 235-244. uille. Med. Trop., 32: 193-197. 
12. Haley, A., 1976. Roots. Doubleday, Garden City, 24. Brown, R. E., and Katz, M., 1966. Failure of an- 
New York, p. 688. tibody production to yellow fever vaccine in chil- 
13. Germain, M., Francy, D. B., Monath, T. P., Fer- dren with kwashiorkor. Trop. Geogr. Med., 18: 
naudet, J. ,  Adam, C., and Digoutte, J.-P., 
8. Monath, T. P., Craven, R. B., Muth, D. J., Trautt, 46: 645-651. 
29: 624-634. 2 91-299. 
partment of Health, Education, and Welfare. Hyg., 73: 341-344. 
rara, L., Bryan, J., Salaun, J.-J., Heme, G., Re- 125-128. 
I 
l 
!I 
II 
I 
’, 
f 

